PURPOSE: To correlate polymorphisms in genes involved in the transport, activation, and inactivation of pemetrexed with the outcome of patients with advanced non-small cell lung cancer (NSCLC) treated withpemetrexed. EXPERIMENTAL DESIGN: Data from a phase II NSCLC trial evaluating the optimal schedule of gemcitabine and pemetrexed were used. All patients with available DNA were genotyped for polymorphisms in FPGS, GGH, and SLC19A1 genes. Patients with various genotypes were compared for efficacy and adverse events resulting from pemetrexed. RESULTS: Fifty-four patients had genotype results for all polymorphisms studied. Patients with the homozygous variant genotypes for SLC19A1 IVS4(2117) C>T, IVS5(9148) C>A, and wild-type genotype for exon6(2522) C>T had a significantly better overall survival compared with their counterparts (median overall survival in months: 8.9 [CC] versus 14.0 [CT] versus 16.7 [TT]; 9.4 [CC] versus 10.3 [CA] versus 22.7 [AA]; and 22.7 [CC] versus 10.3 [CT] versus 9.4 [TT] respectively; all log rank p = 0.03). Patients with the heterozygous TC genotype for GGH IVS5(1042) T>C had greater rates of confirmed response + stable disease compared with the TT genotype (85% versus 60%; odds ratio = 4.0; p = 0.06). A greater risk for grade 3/4 SGPT (ALT) elevation was observed in patients heterozygous (GA) for the FPGS IVS1 (28) G>A polymorphism compared with the GG genotype (43% versus 13%; odds ratio = 5.0, p = 0.07). All results were largely consistent within patients with nonsquamous (n = 40) histology. CONCLUSION: Polymorphisms in SLC1A91 seem to predict for survival differences in pemetrexed-treated NSCLC. Additionally, polymorphisms in GGH and FPGS have marginal associations with response and adverse event. These results should be validated in larger prospective studies using pemetrexed.
RCT Entities:
PURPOSE: To correlate polymorphisms in genes involved in the transport, activation, and inactivation of pemetrexed with the outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with pemetrexed. EXPERIMENTAL DESIGN: Data from a phase II NSCLC trial evaluating the optimal schedule of gemcitabine and pemetrexed were used. All patients with available DNA were genotyped for polymorphisms in FPGS, GGH, and SLC19A1 genes. Patients with various genotypes were compared for efficacy and adverse events resulting from pemetrexed. RESULTS: Fifty-four patients had genotype results for all polymorphisms studied. Patients with the homozygous variant genotypes for SLC19A1 IVS4(2117) C>T, IVS5(9148) C>A, and wild-type genotype for exon6(2522) C>T had a significantly better overall survival compared with their counterparts (median overall survival in months: 8.9 [CC] versus 14.0 [CT] versus 16.7 [TT]; 9.4 [CC] versus 10.3 [CA] versus 22.7 [AA]; and 22.7 [CC] versus 10.3 [CT] versus 9.4 [TT] respectively; all log rank p = 0.03). Patients with the heterozygous TC genotype for GGH IVS5(1042) T>C had greater rates of confirmed response + stable disease compared with the TT genotype (85% versus 60%; odds ratio = 4.0; p = 0.06). A greater risk for grade 3/4 SGPT (ALT) elevation was observed in patients heterozygous (GA) for the FPGS IVS1 (28) G>A polymorphism compared with the GG genotype (43% versus 13%; odds ratio = 5.0, p = 0.07). All results were largely consistent within patients with nonsquamous (n = 40) histology. CONCLUSION: Polymorphisms in SLC1A91 seem to predict for survival differences in pemetrexed-treated NSCLC. Additionally, polymorphisms in GGH and FPGS have marginal associations with response and adverse event. These results should be validated in larger prospective studies using pemetrexed.
Authors: G Liu; S Gurubhagavatula; W Zhou; Z Wang; B Y Yeap; K Asomaning; L Su; R Heist; T J Lynch; D C Christiani Journal: Pharmacogenomics J Date: 2007-03-20 Impact factor: 3.550
Authors: Cynthia X Ma; Suresh Nair; Sachdev Thomas; Sumithra J Mandrekar; Daniel A Nikcevich; Kendrith M Rowland; Tom R Fitch; Harold E Windschitl; Shauna L Hillman; Steven E Schild; James R Jett; Coleman Obasaju; Alex A Adjei Journal: J Clin Oncol Date: 2005-09-01 Impact factor: 44.544
Authors: Alex A Adjei; Sumithra J Mandrekar; Grace K Dy; Julian R Molina; Araba A Adjei; David R Gandara; Katie L Allen Ziegler; Philip J Stella; Kendrith M Rowland; Steven E Schild; Ralph G Zinner Journal: J Clin Oncol Date: 2009-10-19 Impact factor: 44.544
Authors: Esti Liani; Lilah Rothem; Marlene A Bunni; Clyde A Smith; Gerrit Jansen; Yehuda G Assaraf Journal: Int J Cancer Date: 2003-02-20 Impact factor: 7.396
Authors: Charles M Rudin; Wanqing Liu; Apurva Desai; Theodore Karrison; Xuemin Jiang; Linda Janisch; Soma Das; Jacqueline Ramirez; Balasubramanian Poonkuzhali; Erin Schuetz; Donna Lee Fackenthal; Peixian Chen; Deborah K Armstrong; Julie R Brahmer; Gini F Fleming; Everett E Vokes; Michael A Carducci; Mark J Ratain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: G R Westerhof; J H Schornagel; I Kathmann; A L Jackman; A Rosowsky; R A Forsch; J B Hynes; F T Boyle; G J Peters; H M Pinedo Journal: Mol Pharmacol Date: 1995-09 Impact factor: 4.436
Authors: Helen K Chew; James H Doroshow; Paul Frankel; Kim A Margolin; George Somlo; Heinz-Josef Lenz; Michael Gordon; Wu Zhang; Dongyun Yang; Christy Russell; Darcy Spicer; Tim Synold; Robert Bayer; Alexander Hantel; Patrick J Stiff; Merry L Tetef; David R Gandara; Kathy S Albain Journal: J Clin Oncol Date: 2009-03-23 Impact factor: 44.544
Authors: Grace K Dy; Julian R Molina; Yingwei Qi; Rafat Ansari; Sachdev Thomas; Helen J Ross; Gamini Soori; Daniel Anderson; Marie Christine Aubry; Jeffrey Meyers; Araba A Adjei; Sumithra Mandrekar; Alex A Adjei Journal: J Thorac Oncol Date: 2014-08 Impact factor: 15.609
Authors: Carlos Alvarez-Fernandez; Quionia Perez-Arnillas; Lucrecia Ruiz-Echeverria; David Rodriguez-Rubi; Luisa Sanchez-Lorenzo; Walter Li-Torres; Marta Izquierdo-Manuel; Jose P Berros; Maria Luque-Cabal; Paula Jimenez-Fonseca; Noemi Villanueva-Palicio; Emilio Esteban-Gonzalez Journal: Invest New Drugs Date: 2013-08-04 Impact factor: 3.850
Authors: Dal Yong Kim; Dae Ho Lee; Sun-Joo Jang; Sang-We Kim; Cheolwon Suh; Jung Shin Lee Journal: Cancer Res Treat Date: 2011-12-27 Impact factor: 4.679